Premium
Response to pegylated interferon and ribavirin in Asian American patients with Chronic hepatitis C genotypes 1 vs 2/3 vs 6
Author(s) -
Nguyen N. H.,
VuTien P.,
Garcia R. T.,
Trinh H.,
Nguyen H.,
Nguyen K.,
Levitt B.,
Nguyen M. H.
Publication year - 2010
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1111/j.1365-2893.2009.01226.x
Subject(s) - ribavirin , medicine , pegylated interferon , gastroenterology , genotype , depression (economics) , cohort , viral load , retrospective cohort study , hepatitis c virus , hepatitis c , immunology , virus , biology , biochemistry , macroeconomics , economics , gene
Summary. Chronic hepatitis C is generally underappreciated in Asian Americans, and most pivotal studies were conducted in western countries and only included a small numbers of Asian patients. Our goal was to examine and compare treatment outcomes in these patients with genotypes 1 vs 2/3 vs 6. We performed a retrospective cohort study of 167 consecutive treatment‐naïve Asian American patients treated with pegylated interferon (PEG IFN) plus ribavirin (RBV) at two community clinics in Northern California from 12/00 to 1/08. Primary outcome was sustained virological response rate by intention‐to‐treat analysis. The overall completion rate was 76%, and treatment adherence (completion of ≥75–80% PEG IFN + RBV dose for ≥75–80% of intended duration) was 74%. Significant depression was noted in only 4% of patients. Sustained virologic response in patients with genotype 6 treated for 48 weeks was similar to that seen in those with genotype 2/3 (74% vs 75%, P = 0.89) and significantly higher than those with genotype 1 (74% vs 49%, P = 0.016). On multivariate analysis inclusive of sex, age, body mass index (≤25 vs >25) and viral load, only treatment adherence and genotype (2/3 and 6 treated for 48 weeks) were found to be significant predictors of sustained virologic response. We conclude that s ignificant depression is rare in Asian American patients (4%). Patients with genotype 6 treated for 48 weeks appear to have a similar treatment response rate as patients with genotype 2/3 and a significantly higher response rate than those with genotype 1.